The role of amine oxidases in xenobiotic metabolism

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 4, 2006, Pages 559-571

  Gong, Bin ^a   Boor, Paul J ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Monoamine oxidases; Polyamine oxidases; Semicarbazide sensitive amine oxidases; Xenobiotic metabolism

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); FLAVINE ADENINE NUCLEOTIDE; POLYAMINE OXIDASE; SEMICARBAZIDE; XENOBIOTIC AGENT; AMINE OXIDASE (COPPER CONTAINING); AMINE OXIDASE, MIXED FUNCTION; OXIDOREDUCTASE;

DIABETES MELLITUS; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; INFLAMMATION; REVIEW; ADDICTION; ALCOHOLISM; ENZYMOLOGY; METABOLISM; SMOKING;

MAMMALIA;

ALCOHOLISM; AMINE OXIDASE (COPPER-CONTAINING); HUMANS; MONOAMINE OXIDASE; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; SMOKING; SUBSTANCE-RELATED DISORDERS; XENOBIOTICS;

EID: 33747845619     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.4.559     Document Type: Review

References (122)

1. LYLES GA: Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Int J. Biochem. Cell Biol. (1996) 28(3):259-274.
2. BENEDETTI MS: Biotransformation of xenobiotics by amine oxidases. Fundam. Clin. Pharmacol. (2001) 15(2):75-84.
3. SEILER N: Catabolism of polyamines. Amino Acids (2004) 26(3):217-233.
4. SMITH-MUNGO LI, KAGAN HM: Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol. (1997) 16(98):387-398.
5. BOOR PJ, HYSMITH RM, SANDUJA R: A role for a new vascular enzyme in the metabolism of xenobiotic amines. Circ. Res. (1990) 66(1):249-252.
6. LYLES GA: Properties of mammalian tissue-bound semicarbazide-sensitive amine oxidase: possible clues to its physiological function? J. Neural Transm. Suppl. (1994) 41:387-396.
7. YU PH, WRIGHT S, FAN EH, LUN ZR, GUBISNE-HARBERLE D: Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim. Biophys. Acta (2003) 1647(1-2):193-199.
8. GILLAM EM: Exploring the potential of xenobiotic-metabolising enzymes as biocatalysts: evolving designer catalysts from polyfunctional cytochrome P450 enzymes. Clin. Exp. Pharmacol. Physiol. (2005) 32(3):147-152.
9. DORNE JL, WALTON K, RENWICK AG: Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem. Toxicol. (2005) 43(2):203-216.
10. BENEDETTI MS, DOSTERT P, TIPTON KF: Contributiom of monoamine oxidase to the metabolism of xenobiotics. Prog. Drug Metab. (1988) 11:149-174.
11. BENEDETTI MS, DOSTERT P: Contribution of amine oxidases to the metabolism of xenobiotics. Drug Metab. Rev. (1994) 26(3):507-535.
12. BENEDETTI MS, TIPTON KF: Monoamine oxidases and related smine oxidises as phase I enzymes in the metabolism of xenobiotics. J. Neural Transm. Suppl. (1998) 52:149-171.
13. BENEDETTI MS, ALLIEVIE C, COCCHIARA G, PEVARELLO P, DOSTERT P: Involvement of FAD-dependent polyamine oxidase in the metabolism of milacemide in the rat. Xenobiotica (1992) 22:191-197.
14. YU PH: Oxidative deamination of aliphatic amines by rat aorta semicarbazide-sensitive amine oxidase. J. Pharm. Pharmacol. (1990) 42(12):882-884.
15. BARSKY J, PACHA WL, SARKAR S, ZELLER EA: Amine oxidases. XVII. Mode of action of 1-isonicotinyl-2-isopropylhydrazine on monoamine oxidase. J. Biol. Chem. (1959) 234(2):389-391.
16. SHIH JC, CHEN K, RIDD MJ: Monoamine oxidase: from genes to behavior. Ann. Rev. Neurosci. (1999) 22:197-217.
17. EDMONDSON DE, MATTEVI A, BINDA C, LI M, HUBALEK F: Structure and mechanism of monoamine oxidase. Curr. Med. Chem. (2004) 11(15):1983-1993.
18. KALGUTKAR AS, DALVIE DK, CASTAGNOLI N Jr, TAYLOR TJ: Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol. (2001) 14(9):1139-1162.
19. BACH AW, LAN NC, JOHNSON DL et al.: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. USA (1988) 85(13):4934-4938.
20. CESURA AM, PLETSCHER A: The new generation of monoamine oxidase inhibitors. Prog. Drug Res. (1992) 38:171-297.
21. INOUE H, CASTAGNOLI K, VAN DER SCHYF C, MABIC S, IGARASHI K, CASTAGNOLI N Jr: Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives. J. Pharmacol. Exp. Ther. (1999) 291(2):856-864.
22. TIPTON KF, BOYCE S, O'SULLIVAN J, DAVEY GP, HEALY J: Monoamine oxidases: certainties and uncertainties. Curr. Med. Chem. (2004) 11(15):1965-1982.
23. SAURA J, NADAL E, VAN DEN BB, VILA M, BOMBI JA, MAHY N: Localization of monoamine oxidases in human peripheral tissues. Life Sci. (1996) 59(16):1341-1349.
24. SHIH JC, CHEN K: Regulation of MAO-A and MAO-B gene expression. Curr. Med. Chem. (2004) 11(15):1995-2005.
25. BERRY MD, JUORIO AV, PATERSON IA: The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog. Neurobiol. (1994) 42(3):375-391.
26. ANDERSON AH, KUTTAB S, CASTAGNOLI N Jr: Deuterium isotope effect studies on the MAO-B catalyzed oxidation of 4-benzyl-1-cyclopropyl-1,2,3,6- tetrahydropyridine. Biochemistry (1996) 35(10):3335-3340.
27. KALGUTKAR AS, CASTAGNOLI N Jr: Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Med. Res. Rev. (1995) 15(4):325-388.
28. YOUDIM MB, WEINSTOCK M: Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant ryramine potentiation. Neurotoxicology (2004) 25(1-2):243-250.
29. SHULMAN KI, WALKER SE: Refining the MAOI diet: tyramine content of pizzas and soy products. J. Clin. Psychiatry (1999) 60(3):191-193.
30. FEINBERG SS, HOLZER B: The monoamine oxidase inhibitor (MAOI) diet and kosher pizza. J. Clin. Psychopharmacol. (1997) 17(3):226-227.
31. FEINBERG S, HOLZER B: Clarifying the safety of the MAOI diet and pizza. J. Clin. Psychiatry (2000) 61(2):145-146.
32. WALKER SE, SHULMAN KI, TAILOR SA, GARDNER D: Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J. Clin. Pychopharmacol. (1996) 16(5):383-388.
33. GARDNER DM, SHULMAN KI, WALKER SE, TAILOR SA: The making of a user friendly MAOI diet. J. Clin. Psychiatry (1996) 57(3):99-104.
34. WEINSTOCK M, BEJAR C, WANG RH et al.: TV-3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. Suppl. (2000) 60:157-169.
35. TETRUD JW, LANGSTON JW: MPTP-induced parkinsonism as a model for Parkinsons disease. Acta Neurol. Scand. Suppl. (1989) 126:35-40.
36. LANGSTON JW, IRWIN I, LANGSTON EB, FORNO LS: Pargyline prevents MPTP-induced parkinsonism in primates. Science (1984) 225(4669):1480-1482.
37. KUPSCH A, SAUTTER J, GOTZ ME et al.: Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm. (2001) 108(8-9):985-1009.
38. KRUEGER MJ, EFANGE SM, MICHELSON RH, SINGER TP: Interaction of flexible analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of N-methyl-4-phenylpyridinium with highly purified monoamine oxidase A and B. Biochemistry (1992) 31(24):5611-5615.
39. TREVOR AJ, CASTAGNOLI N, SINGER TP: The formation of reactive intermediates in the MAO-catalyzed oxidation of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-terrahydropyridine (MPTP). Toxicology (1988) 49(2-3):513-519.
40. TAKAHATA K, SHIMAZU S, YONEDA F, OGAWA M, IIDA Y, SAJI H: Effects of monoamine oxidase inhibitors on thediethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice. J. Neural Transm. (2003) 110(8):859-869.
41. LANGSTON JW, BALLARD P: Parkinsonism induced by 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can. J. Neurol. Sci. (1984) 11(1 Suppl.):160-165.
42. CHIBA K, TREVOR A, CASTAGNOLI N Jr: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. (1984) 120(2):574-578.
43. FOURNIER P: Biotransformation of dimethylnitrosamine. J. Toxicol. Clin. Exp. (1990) 10(5):283-296.
44. PHILLIPS JC, BEX C, LAKE BG, COTTRELL RC, GANGOLLI SD: Inhibition of dimethylnitrosamine metabolism by some heterocyclic compounds and by substrates and inhibitors of monoamine oxidase in the rat. Cancer Res. (1982) 42(9):3761-3765.
45. LAKE BG, HARRIS RA, COLLINS MA, COTTRELL RC, PHILLIPS JC, GANGOLLI SD: Studies on the metabolism of dimethylnitrosamine in vitro by rat-liver preparations. II. Inhibition by substrates and inhibitors of monoamine oxidase. Xenobiotica (1982) 12(9):567-579.
46. LAI DY, MYERS SC, WOO YT et al.: Role of dimethylnitrosamine- demethylase in the metabolic activation of dimethylinitrosamine. Chem. Biol. Interact. (1979) 28(1):107-126.
47. HASHIMOTO M, MUKASA H, YAMADA S, NAKAMURA J, INANAGA K: Frontal midline theta activity and platelet MAO in human subjects. Biol Psychiatry (1988) 23(1):31-43.
48. BUCHSBAUM MS, COURSEY RD, MURPHY DL: The biochemical high-risk paradigm: behavioral and familial correlates of low platelet monoamine oxidase activity. Science (1976) 194(4262):339-341.
49. MACEDO T, RIBEIRO CA, COTRIM D et al.: Catecholamine and MHPG plasma levels, platelet MAO activity, and 3H-imipramine binding in heroin and cocaine addicts. Mol. Neurobiol. (1995) 11(1-3):21-29.
50. ORELAND L: Platelet monoamine oxidase, personality and alcoholism: the rise, fall and resurrection. Neurotoxicology (2004) 25(1-2):79-89.
51. KUHAR MJ, RITZ MC, BOJA JW: The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. (1991) 14(7):299-302.
52. WAYMENT HK, SCHENK JO, SORG BA: Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. J. Neurosci. (2001) 21(1):35-44.
53. PEPPER JP, BAUMANN MH, AYESTAS M, ROTHMAN RB: Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens. Brain Res. Mol. Brain Res. (2001) 87(2):184-189.
54. HABERNY KA, WALSH SL, GINN DH et al.: Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend. (1995) 39(1):55-62.
55. GERLACH M, YOUDIM MB, RIEDERER P: Pharmacology of selegiline. Neurology (1996) 47(6 Suppl. 3):S137-S145.
56. MUKASA H, NAKAMURA J, YAMADA S, INOUE M, NAKAZAWA Y: Platelet monoamine oxidase activity and personality traits in alcoholics and methamphetamine dependents. Drug Alcohol Depend. (1990) 26(3):251-254.
57. ORELAND L, FOWLER CJ, SCHALLING D: Low platelet monoamine oxidase activity in cigarette smokers. Life Sci. (1981) 29(24):2511-2518.
58. FOWLER JS, LOGAN J, VOLKOW ND, WANG GJ, MACGREGOR RR, DING YS: Monoamine oxidase: radiotracer development and human studies. Methods (2002) 27(3):263-277.
59. FOWLER JS, VOLKOW ND, WANG GJ et al.: Inhibition of monoamine oxidase B in the brains of smokers. Nature (1996) 379(6567):733-736.
60. FOWLER JS, VOLKOW ND, WANG GJ et al.: Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. USA (1996) 93(24):14065-14069.
61. HERRAIZ T, CHAPARRO C: Human monoamine oxidase is inhibited by tobacco smoke: β-carboline alkaloids act as potent and reversible inhibitors. Biochem. Biophys. Res. Commun. (2005) 326(2):378-386.
62. HUGHES JR, HATSUKAMI DK, MITCHELL JE, DAHLGREN LA: Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry (1986) 143(8):993-997.
63. GOTTFRIES CG, ORELAND L, WIBERG A, WINBLAD B: Lowered monoamine oxidase activity in brains from alcoholic suicides. J. Neurochem. (1975) 25(5):667-673.
64. WIBERG A, GOTTFRIES CG, ORELAND L: Low platelet monoamine oxidase activity in human alcoholics. Med. Biol. (1977) 55(3):181-186.
65. CLONINGER CR, BOHMAN M, SIGVARDSSON S: Inheritance of alcohol abuse. Cross-fostering analysis of adopted men. Arch. Gen. Psychiatry (1981) 38(8):861-868.
66. FAHLKE C, GARPENSTRAND H, ORELAND L, SUOMI SJ, HIGLEY JD: Platelet monoamine oxidase activity in a nonhuman primate model of type 2 excessive alcohol consumption. Am. J. Pychiatry (2002) 159(12):2107.
67. SNELL LD, GLANZ J, TABAKOFF B: Relationships between effects of smoking, gender, and alcohol dependence on platelet monoamine oxidase-B: activity, affinity labeling, and protein measurements. Alcohol. Clin. Exp. Res. (2002) 26(7):1105-1113.
68. FARREN CK, CLARE AW, TIPTON KF, DINAN TG: Platelet MAO activity in subtypes of alcoholics and controls in a homogenous population. J. Psychiatr. Res. (1998) 32(1):49-54.
69. WHITFIELD JB, PANG D, BUCHOLZ KK et al.: Monoamine oxidase: associations with alcohol dependence, smoking and other measures of psychopathology. Psychol. Med. (2000) 30(2):443-454.
70. TIPNIS UR, HE GY, LI S, CAMPBELL G, BOOR PJ: Attenuation of isoproterenol-mediated myocardial injury in rat by an inhibitor of polyamine synthesis. Cardiovasc. Pathol. (2000) 9(5):273-280.
71. AGOSTINELLI E, ARANCIA G, VEDOVA LD et al.: The biological functions of polyamine oxidation products by amine oxidases: perspectives of clinical applications. Amino Acids (2004) 27(3-4):347-358.
72. AGOSTINELLI E: Introduction: amine oxidases and polyamines in biological systems. Amino Acids (2004) 27(3-4):345-346.
73. SEILER N, DURANTON B, RAUL F: The polyamine oxidase inactivator MDL-72527. Prog. Drug Res. (2002) 59:1-40.
74. KWAK MK, KENSLER TW, CASERO RA Jr: Induction of phase II enzymes by serum oxidized polyamines through activation of Nrf2: effect of the polyamine metabolite acrolein. Biochem. Biophys. Res. Commun. (2003) 305(3):662-670.
75. SHARMIN S, SAKATA K, KASHIWAGI K et al.: Polyamine cytotoxicity in the presence of bovine serum amine oxidase. Biochem. Biophys. Res. Commun. (2001) 282(1):228-235.
76. PACKHAM G, CLEVELAND JL: Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol. Cell. Biol. (1994) 14(9):5741-5747.
77. FLESCHER E, FOSSUM D, TALAL N: Polyamine-dependent production of lymphocytotoxic levels of ammonia by human peripheral blood monocytes. Immunol. Lett. (1991) 28(1):85-89.
78. O'SULLIVAN J, UNZETA M, HEALY J, O'SULLIVAN MI, DAVEY G, TIPTON KF: Semicarbazide-sensitive amine oxidases: enzymes with quite a lot to do. Neurotoxicology (2004) 25(1-2):303-315.
79. BOOMSMA F, DERKX FH, VAN DEN MEIRACKER AH, MAN IN 'T VELD AJ, SCHALEKAMP MA: Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. Clin. Sci. (Lond) (1995) 88(6):675-679.
80. HYSMITH RM, BOOR PJ: In vitro expression of benzylamine oxidase activity in cultured porcine smooth muscle cells. J. Cardiovasc. Pharmacol. (1987) 9(6):668-674.
81. LYLES GA, SINGH I: Vascular smooth muscle cells: a major source of the semicarbazide-sensitive amine oxidase of the rat aorta. J. Pharm. Pharmacol. (1985) 37(9):637-643.
82. O'SULLIVAN M, TIPTON KF, MCDEVITT WE: Immunolocalization of semicarbazide-sensitive amine oxidase in human dental pulp and its activity towards serotonin. Arch. Oral Biol. (2002) 47(5):399-406.
83. LIZCANO JM, F ERNANDEZ DE ARRIBA A, LYLES GA, UNZETA M: Several aspects on the amine oxidation by semicarbazide-sensitive amine oxidise (SSAO) from bovine lung. J. Neural Transm. Suppl. (1994) 41:415-420.
84. ZHANG X, MCINTIRE WS: Cloning and sequencing of a copper-containing, topaquinone-containing monoamine oxidase from human placenta. Gene (1996) 179(2):279-286.
85. CRONIN CN, ZHANG X, THOMPSON DA, MCINTIRE WS: cDNA cloning of two splice variants of a human copper-containing monoamine oxidase pseudogene containing a dimeric Alu repeat sequence. Gene (1998) 220(1-2):71-76.
86. IMAMURA Y, KUBOTA R, WANG Y et al.: Human retina-specific amine oxidase (RAO): cDNA cloning, tissue expression, and chromosomal mapping. Genomics (1997) 40(2):277-283.
87. MOLDES M, FEVE B, PAIRAULT J: Molecular cloning of a major mRNA species in murine 3T3 adipocyte lineage, differentiation-dependent expression, regulation, and identification as semicarbazide-sensitive amine oxidase. J. Biol. Chem. (1999) 274(14):9515-9523.
88. SMITH DJ, SALMI M, BONO P, HELLMAN J, LEU T, JALKANEN S: Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J. Exp. Med. (1998) 188(1):17-27.
89. JAAKKOLA K, KAUNISMAKI K, TOHKA S et al.: Human vascular adhesion protein-1 in smooth muscle cells. Am. J. Pathol. (1999) 155(6):1953-1965.
90. BONO P, SALMI M, SMITH DJ et al.: Isolation, structural characterization, and chromosomal mapping of the mouse vascular adhesion protein-1 gene and promoter. J. Immunol. (1998) 161(6):2953-2960.
91. BONO P, SALMI M, SMITH DJ, JALKANEN S: Cloning and characterization of mouse vascular adhesion protein-1 reveals a novel molecule with enzymatic activity. J. Immunol. (1998) 160(11):5563-5571.
92. SALMI M, JALKANEN S: VAP-1: an adhesin and an enzyme. Trends Immunol. (2001) 22(4):211-216.
93. BOOR PJ, NELSON TJ: Allylamine cardiotoxicity: III. Protection by semicarbazide and in vivo derangements of monoamine oxidase. Toxicology (1980) 18(2):87-102.
94. BOOR PJ, NELSON TJ: Bio transformation of the cardiovascular toxin, allylamine, by rat and human cardiovascular tissue. J. Mol. Cell. Cardiol. (1982) 14(11):679-682.
95. BOOMSMA F, HUT H, BAGGHOE U, VAN DER HA, VAN DEN MA: Semicarbazide- sensitive amine oxidase (SSAO): from cell to circulation. Med. Sci. Monit. (2005) 11(4):RA122-RA126.
96. ARDANAZ N, PAGANO PJ: Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp. Biol. Med. (Maywood) (2006) 231(3):237-251.
97. TOTH B, SHIMIZU H: 1-Carbamyl-2-phenylhydrazine tumorigenesis in Swiss mice. Morphology of lung adenomas. J. Natl. Cancer Inst. (1974) 52(1):241-251.
98. TOTH B, SHUMIZU H, ERICKSON J: Carbamylhydrazine hydrochloride as a lung and blood vessel tumour inducer in Swiss mice. Eur. J. Cancer (1975) 11(1):17-22.
99. MORI K, YASUNO A, MATSUMOTO K: Induction of pulmonary tumors in mice with isonicotinic acid hydrazid. Gann (1960) 51:83-90.
100. BHATTACHARYA K: Chromosome damage induced by semicarbazide in spermatocytes of a grasshopper. Mutat. Res. (1976) 40(3):237-242.
101. STEFFEK AJ, VERRUSIO AC, WATKINS CA: Cleft palate in rodents after maternal treatment with various lathyrogenic agents. Teratology (1972) 5(1):33-38.
102. LANGFORD SD, TRENT MB, BALAKUMARAN A, BOOR PJ: Developmental vasculotoxicity associated with inhibition of semicarbazide-sensitive amine oxidase. Toxicol. Appl. Pharmacol. (1999) 155(3):237-244.
103. KINEMUCHI H, SUGIMOTO H, OBATA T, SATOH N, UEDA S: Selective inhibitors of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) activity in mammalian tissues. Neurotoxicology (2004) 25(1-2):325-335.
104. LANGFORD SD, TRENT MB, BOOR PJ: Semicarbazide-sensitive amine oxidase and extracellular matrix deposition by smooth-muscle cells. Cardiovasc. Toxicol. (2002) 2(2):141-150.
105. CONKLIN DJ, BOOR PJ: Allylamine cardiovascular toxicity: evidence for aberrant vasoreactivity in rats. Toxicol. Appl. Pharmacol. (1998) 148(2):245-251.
106. CONKLIN DJ, BOYCE CL, TRENT MB, BOOR PJ: Amine metabolism: a novel path to coronary artery vasospasm. Toxicol. Appl. Pharmacol. (2001) 175(2):149-159.
107. CONKLIN DJ, COWLEY HR, WIECHMANN RJ, JOHNSON GH, TRENT MB, BOOR PJ: Vasoactive effects of methylamine in isolated human blood vessels: role of semicarbazide-sensitive amine oxidase, formaldehyde, and hydrogen peroxide. Am. J. Physiol. Heart Circ. Physiol. (2004) 286(2):H667-H676.
108. GONG B, TRENT MB, SRIVASTAVA D, BOOR PJ: Chemical-induced, nonlethal, developmental model of dissecting aortic aneurysm. Birth Defects Res. A Clin. Mol. Teratol. (2006) 76(1):29-38.
109. GONG B, WANG L, SUN J et al.: Quantitative morphologic assessment on extracellular matrix in chemical-induced developmental dissecting aortic aneurysm using multiphoton florescence and second harmonic generation microscopy [abstract]. The 13th Weinstein Cardiovascular Development Conference. St Petersburg, Florida, USA (2006):29.
110. LIZCANO JM, TIPTON KF, UNZETA M: Purification and characterization of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) from bovine lung. Biochem. J. (1998) 331(Pt 1):69-78.
111. ELLIOTT J, CALLINGHAM BA, SHARMAN DF: Metabolism of amines in the isolated perfused mesenteric arterial bed of the rat. Br. J. Pharmacol. (1989) 98(2):507-514.
112. NELSON TJ, BOOR PJ: Allylamine cardiotoxicity - IV. Metabolism to acrolein by cardiovascular tissues. Biochem. Pharmacol. (1982) 31(4):509-514.
113. BOOR PJ, HYSMITH RM: Allylamine cardiovascular toxicity. Toxicology (1987) 44(2):129-145.
114. AWASTHI S, BOOR PJ: Semicarbazide protection from in vivo oxidant injury of vascular tissue by allylamine. Toxicol. Lett. (1993) 66(2):157-163.
115. RAMOS K, GROSSMAN SL, COX LR: Allylamine-induced vascular toxicity in vitro: prevention by semicarbazide-sensitive amine oxidase inhibitors. Toxicol. Appl. Pharmacol. (1988) 95(1):61-71.
116. PRECIOUS E, GUNN CE, LYLES GA: Deamination of methylamine by semicarbazide-sensitive amine oxidise in human umbilical artery and rat aorta. Biochem. Pharmacol. (1988) 37(4):707-713.
117. LYLES GA, MCDOUGALL SA: The enhanced daily excretion of urinary methylamine in rats treated with semicarbazide or hydralazine may be related to the inhibition of semicarbazide-sensitive amine oxidase activities. J. Pharm. Pharmacol. (1989) 41(2):97-100.
118. YU PH, ZUO DM: Formaldehyde produced endogenously via deamination of methylamine. A potential risk factor for initiation of endothelial injury. Atherosclerosis (1996) 120(1-2):189-197.
119. BOOMSMA F, PEDERSEN-BJERGAARD U, GERHOLM-LARSEN B et al.: Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with Type 1 diabetes mellitus. Diabetologia (2005) 48(5):1002-1007.
120. BOOMSMA F, BHAGGOE UM, VAN DER HOUWEN AM, VAN DEN MEIRACKER AH: Plasma semicarbazide-sensitive amine oxidase in human (patho)physiology. Biochim. Biophys. Acta (2003) 1647(1-2):48-54.
121. BOOMSMA F, DE KAM PJ, TJEERDSMA G, VAN DEN MEIRACKER AH, VAN VELDHUISEN DJ: Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur. Heart J. (2000) 21(22):1859-1863.
122. LEWINSOHN R: Human serum amine oxidase. Enzyme activity in severely burnt patients and in patients with cancer. Clin. Chim. Acta (1977) 81(3):247-256.